A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

A study of 3 doses of Progenta versus placebo versus Lucron Depot for treatment of leiomyomata.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Repros Therapeutics Inc.
• Treatments: Leuprolide

Criteria

Inclusion Criteria:

• Had at least one leiomyomata lesion that was identifiable and measurable by transvaginal ultrasound.

• Had a regular or steady menstrual cycle lasting from 24 to 36 days.

Exclusion Criteria:

• Post-menopausal

• Subject with documented endometriosis